platinum sensitive peritoneal cancer
Showing 1 - 25 of >10,000
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine plus Bevacizumab
- Bevacizumab
-
New Orleans, Louisiana
- +3 more
Dec 16, 2022
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)
Not yet recruiting
- Ovary Cancer
- +2 more
- Mirvetuximab Soravtansine
- Olaparib
-
Aurora, ColoradoUniversity of Colorado Hospital
May 30, 2023
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)
Not yet recruiting
- High Grade Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
- Carboplatin
- (no location specified)
Jul 11, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial
Active, not recruiting
- Fallopian Tube Endometrioid Tumor
- +13 more
- Olaparib
- Tremelimumab
-
Orange, California
- +19 more
Jan 10, 2023
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated
Recruiting
- Ovarian Cancer
- +3 more
- ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
-
Blacktown, New South Wales, Australia
- +5 more
Nov 9, 2022
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma
Recruiting
- Recurrent Ovarian Cancer
- +6 more
- Oregovomab
- Niraparib
-
Durham, North Carolina
- +2 more
Jul 26, 2022
Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer Trial in United States (Secondary Cytoreductive Surgery, Carboplatin
Active, not recruiting
- Ovarian Cancer
- +2 more
- Secondary Cytoreductive Surgery
- +2 more
-
Hartford, Connecticut
- +10 more
Feb 23, 2022
Epithelial Ovarian Cancer Trial in Singapore (Oregovomab, Nivolumab, Chemotherapy)
Unknown status
- Epithelial Ovarian Cancer
- Oregovomab
- +2 more
-
Singapore, Singapore
- +1 more
Nov 30, 2021
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (Pazopanib, Doxil)
Terminated
- Ovarian Cancer
- +2 more
-
Fort Myers, Florida
- +3 more
Oct 4, 2021
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma Trial in United
Active, not recruiting
- Metastatic Fallopian Tube Carcinoma
- +11 more
- Berzosertib
- +4 more
-
Phoenix, Arizona
- +13 more
Dec 2, 2022
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial (DCVAC/OvCa, DCVAC/OvCa )
Withdrawn
- Ovarian Cancer
- +2 more
- DCVAC/OvCa
- DCVAC/OvCa placebo
- (no location specified)
Dec 6, 2021
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,
Recruiting
- High Grade Serous Ovarian Cancer
- +2 more
- Upifitimab rilsodotin
- Placebo
-
Phoenix, Arizona
- +40 more
Jan 25, 2023
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Japan (Niraparib)
Active, not recruiting
- Ovarian Cancer
- +2 more
-
Nagoya, Aichi, Japan
- +26 more
Feb 7, 2022
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +3 more
Dec 5, 2022
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
-
Anchorage, Alaska
- +55 more
Jul 25, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Bronx, New York
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Carboplatin
- +2 more
-
Bronx, New York
- +2 more
Oct 18, 2021